-The Times of India NEW DELHI: Jupiter's gravity could be Rahul Gandhi's flourish, but "escape velocity" is a buzzword in macro economics and empowerment this year, figuring in the title of an influential paper by two Harvard economists studying racial inequality. In "Achieving escape velocity: Neighbourhood and school interventions to reduce persistent inequality", Harvard's Roland D Fryer and Lawrence F Katz examine policies that enable youth to "escape the gravitational pull of...

-The Economic Times MUMBAI/ NEW DELHI: For almost eight months, 30-year-old Reena Sahani spurned inappropriate requests by her boss to meet him outside of work. He changed tack, loading her with more work to make her stay back late in office. Finally, emboldened by chats with a company-appointed counsellor, she lodged a complaint. Rooma Sircar, an IT executive, tolerated an innuendo of sexually explicit jokes by a senior male colleague for...

-The Business Standard The next catastrophe to hit UID will be on breach of privacy, which will happen sooner than later Tech czar and soon to be politician Nandan Nilekani joined Twitter last week and already has some 650 plus followers. The man shunned all forms of social media during the last four years as the chief of the unique identify (UID) or Aadhaar project. So this sudden change in strategy is...

-The Hindu More needs to be done to enforce the law banning manual scavenging. This monsoon, India's Parliament passed a law of enormous social significance prohibiting and punishing manual scavenging, which remains the most degrading form of untouchability and caste discrimination in the country. This is not the first time this practice was outlawed: untouchability and forced labour were forbidden in the Constitution itself and, in 1993, a law was first passed...

-Live Mint Apex court expresses concerns about drug trials being permitted on humans without comprehensive rules to regulate the approval process New Delhi: The apex court on Monday directed the health ministry to justify its approval for 162 global clinical trials in India, increasing the uncertainty faced by the nation's $500 million clinical research industry. The Supreme Court expressed its concerns about drug trials being permitted on humans without comprehensive rules to...